Trading Update

NMT Group PLC
18 January 2000

                                Trading Update

NMT Group PLC ('NMT') announces today that it expects its loss for the year
ended 31 December 1999 to be approximately £7.1 million, somewhat higher than
market expectations. The loss includes the write-off of approximately £840,000
in respect of stock that had become obsolete largely due to the lack of sales.
Revenues have grown more slowly than expected and are anticipated to be
approximately £66,000 for the year. However, based on the cash resources of
£8.9 million at the year end and the Company's internal sales forecasts, the
Directors believe that the Company will be able to take advantage of the
future sales potential without recourse to additional equity finance.

The Company scaled down its production and sales and marketing efforts during
the last quarter of 1999 as, following weak sales, it recognised that it was
unable to supply the market's requirements for a broader range of products.
With the introduction of product from the new multi-cannula automated assembly
machine (see below), sales & marketing activity will shortly re-commence in
anticipation of the availability of a full range of 3ml needle sizes to meet
market demand. In addition, the Company is continuing to address the
manufacturing challenges discussed at the time of the Company's interim
results in September 1999. Production output from NMT's first automated
assembly machine has been improved and further improvements are planned for
2000.

In December 1999, the Company also took delivery of its second automated
assembly machine, manufactured by Sortimat Automations GmbH.  This machine,
currently undergoing validation, incorporates many changes derived from
experience with the first machine. It will be able to assemble 3ml syringes
with a range of needle sizes, thus substantially expanding the Company's
product portfolio. Validation of this machine is expected to be completed
within the next few weeks. A further identical 3ml machine is due for delivery
in the second quarter of 2000. In the same quarter the first assembly machine
for 1ml safety syringes, also featuring a range of needle sizes, will be
delivered from Mikron SA, Boudry. Combined annual output from the four
assembly systems is eventually expected to exceed 180 million units. Work
continues on the design and early development of a number of other products.

In November, the Company was awarded a further £3 million in Regional
Selective Assistance, payable over the next two years, subject to the Company
meeting certain employment and capital expenditure targets in accordance with
its business plan.

The increasing adoption of safe needle legislation by individual states in the
US, as well as the enactment of a safe needle regulation by the Occupational
Health and Safety Administration, continues to establish a favourable
environment for the use of safety syringes. Following the recent expansion of
the sales and marketing team in the US in anticipation of the introduction of
a broader range of Zero Stik safety syringes, the Company is now well placed
to exploit the market opportunity.

In a separate announcement today, the Board of NMT has announced that Roy
Smith, currently Chief Executive of Advanced Medical Solutions plc, has been
appointed the Company's new Chief Executive Officer, replacing John Campbell
who has retired from the Company for personal reasons.

Dr. Roger Gilmour, Chairman of NMT, commented: 'With strong new management, a
broader product range, the Company's production challenges in hand and
continuing favourable movements in the vital US marketplace, NMT is well
poised to move forward during the coming year.'

                                
Enquiries:

NMT Group PLC                                  Tel: [phone]
Dr. Roger Gilmour, Chairman
Harry Bocker, Finance Director

Financial Dynamics                             Tel: [phone]
David Yates / Sophie Pender-Cudlip